MedTrace Logo

Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV

NCT00090779 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2018-10-11

Study results available
· View outcomes & findings →

Summary

Although some doctors favor starting anti-HIV treatment as soon as possible after patients learn they are infected, it is not known if treatment for recently infected patients results in long-term benefits or harm. The purpose of this study is to learn whether or not people should take anti-HIV drugs when they are first infected.

Conditions

  • HIV Infections

Interventions

DRUG

Emtricitabine/ tenofovir disoproxil fumarate

once daily

DRUG

Lopinavir/Ritonavir

twice daily

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Adult AIDS Clinical Trials Group

    collaborator NETWORK

  • Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

    lead NETWORK

Principal Investigators

  • Christine Hogan, MD · Division of Infectious Diseases, Columbia University College of Physicians and Surgeons

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2009-07-31
Completion
2011-05-31

Countries

  • United States
  • Peru

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00090779 on ClinicalTrials.gov